Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases
NCT00811174
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
5
Enrollment
INDUSTRY
Sponsor class
Stopped
Due to limited data available, efficacy, and PK analyses were not performed.
Conditions
Immunologic Deficiency Syndromes
Interventions
DRUG:
Octagam 10%
Sponsor
Octapharma